Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis

被引:215
作者
Bhavnani, Sujata M. [1 ]
Rubino, Christopher M. [1 ]
Ambrose, Paul G. [1 ]
Drusano, George L. [1 ]
机构
[1] Ordway Res Inst, Inst Clin Pharmacodynam, Albany, NY 12208 USA
关键词
SINGLE-DOSE PHARMACOKINETICS; SKIN-STRUCTURE INFECTIONS; STAPHYLOCOCCUS-AUREUS; HEALTHY-VOLUNTEERS; COMPLICATED SKIN; SAFETY;
D O I
10.1086/652767
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The objective of this analysis was to evaluate the relationship between daptomycin exposure and the probability of an elevation in the creatine phosphokinase (CPK) level (hereafter, "CPK elevation") in patients with Staphylococcus aureus bacteremia with or without infective endocarditis. Methods. Phase 3 data for patients with S. aureus bacteremia, with or without infective endocarditis, who received intravenous daptomycin (6 mg/kg daily) and in whom pharmacokinetic data were collected were evaluated. On the basis of univariate logistic regression, the relationship between Bayesian post hoc exposure estimates and the probability of a CPK elevation was evaluated. Time to CPK elevation was examined with Kaplan-Meier analysis and Cox proportional hazards regression. Results. Significant relationships between the minimum concentration of drug (C-min) and area under the plasma concentration time curve and probability of CPK elevation were observed in 108 evaluable patients. Of the 108 patients evaluated, 6 (5.56%) demonstrated a defined CPK elevation, regardless of treatment relationship. C-min (breakpoint of 24.3 mg/L) was most significantly associated with CPK elevation (P = .002). The probabilities of a CPK elevation with a C-min >= 24.3 mg/L and <24.3 mg/L were 0.5 and 0.029, respectively. Increases in C-min, evaluated as a continuous variable, were also significantly associated with CPK elevation (P = .01). Stratified Kaplan-Meier analysis and Cox proportional hazards regression demonstrated C min to be a significant predictor of time to a CPK elevation (P <= .003). The probability of a CPK elevation was 0 and 0.01 after 7 days of treatment in patients with a C-min >= 24.3 mg/L or <24.3 mg/L, respectively. After 14 days, the probabilities were 0.5 and 0.025, respectively. Conclusions. This analysis demonstrated that a daptomycin C-min >= 24.3 mg/L was associated with an increased probability of a CPK elevation.
引用
收藏
页码:1568 / 1574
页数:7
相关论文
共 20 条
[1]   The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].
Arbeit, RD ;
Maki, D ;
Tally, FP ;
Campanaro, E ;
Eisenstein, BI .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681
[2]   Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers [J].
Benvenuto, Mark ;
Benziger, David P. ;
Yankelev, Sara ;
Vigliani, Gloria .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) :3245-3249
[3]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[4]  
*CUB PHARM, 2008, CUB DAPT INJ FULL PR
[5]  
DARGENIO DZ, 1997, ADAPT 2 PROGRAM PACK
[6]   Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects [J].
Dvorchik, BH ;
Brazier, D ;
DeBruin, MF ;
Arbeit, RD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1318-1323
[7]   Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus [J].
Fowler, Vance G., Jr. ;
Boucher, Helen W. ;
Corey, G. Ralph ;
Abrutyn, Elias ;
Karchmer, Adolf W. ;
Rupp, Mark E. ;
Levine, Donald P. ;
Chambers, Henry F. ;
Tally, Francis P. ;
Vigliani, Gloria A. ;
Cabell, Christopher H. ;
Link, Arthur Stanley ;
DeMeyer, Ignace ;
Filler, Scott G. ;
Zervos, Marcus ;
Cook, Paul ;
Parsonnet, Jeffrey ;
Bernstein, Jack M. ;
Price, Connie Savor ;
Forrest, Graeme N. ;
Faetkenheuer, Gerd ;
Gareca, Marcelo ;
Rehm, Susan J. ;
Brodt, Hans Reinhardt ;
Tice, Alan ;
Cosgrove, Sara E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (07) :653-665
[8]   Quantification of lean bodyweight [J].
Janmahasatian, S ;
Duffull, SB ;
Ash, S ;
Ward, LC ;
Byrne, NM ;
Green, B .
CLINICAL PHARMACOKINETICS, 2005, 44 (10) :1051-1065
[9]   A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria [J].
Katz, D. E. ;
Lindfield, K. C. ;
Steenbergen, J. N. ;
Benziger, D. P. ;
Blackerby, K. J. ;
Knapp, A. G. ;
Martone, W. J. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (09) :1455-1464
[10]   An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) population models [J].
Leary, R ;
Jelliffe, R ;
Schumitzky, A ;
Van Guilder, M .
FOURTEENTH IEEE SYMPOSIUM ON COMPUTER-BASED MEDICAL SYSTEMS, PROCEEDINGS, 2001, :389-394